FCGR3A and asthma: There was a significant decrease in CD16 MFI expression in patients with moderate and severe asthma in the intermediate (CD14++CD16+) monocyte subset and also in the non-classical (CD14+CD16++) subset in patients with severe asthma compared to healthy controls.